Carey DL - Search Results

1

Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.

Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S; INITIO Trial International Coordinating Committee. Wand H, et al. Among authors: carey dl. AIDS. 2007 Nov 30;21(18):2445-53. doi: 10.1097/QAD.0b013e3282efad32. AIDS. 2007. PMID: 18025881 Clinical Trial.

2

Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.

Kovacic JC, Martin A, Carey D, Wand H, Mallon PW, Feneley MP, Emery S, Cooper DA, Carr A; ROSEY Investigators. Kovacic JC, et al. Antivir Ther. 2005;10(1):135-43. Antivir Ther. 2005. PMID: 15751771 Clinical Trial.

3

Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial.

Carey D, Wand H, Martin A, Rothwell S, Emery S, Cooper DA, Carr A; Rosey Investigators. Carey D, et al. AIDS. 2005 Aug 12;19(12):1325-7. doi: 10.1097/01.aids.0000180106.11383.cc. AIDS. 2005. PMID: 16052090 Clinical Trial.

4

Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.

Read TR, Carey D, Mallon P, Mijch A, Goodall R, Hudson F, Wand H, Emery S. Read TR, et al. AIDS. 2009 Oct 23;23(16):2222-3. doi: 10.1097/QAD.0b013e32832e95f8. AIDS. 2009. PMID: 19773634

5

A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy.

Carey DL, Baker D, Rogers GD, Petoumenos K, Chuah J, Easey N, Machon K, Cooper DA, Emery S, Carr A; Facial LipoAtrophy Study in HIV Investigators. Carey DL, et al. J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):581-9. doi: 10.1097/qai.0b013e318158bec9. J Acquir Immune Defic Syndr. 2007. PMID: 18193500 Clinical Trial.

6

A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.

Carey D, Pett SL, Bloch M, Wand H, MacRae K, Beileiter K, Ray JE, Boyd MA, Emery S, Cooper DA. Carey D, et al. J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):143-9. doi: 10.1097/QAI.0b013e318252f97e. J Acquir Immune Defic Syndr. 2012. PMID: 22421745 Clinical Trial.

7

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.

Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R. Dickinson L, et al. Clin Pharmacokinet. 2016 Jul;55(7):861-873. doi: 10.1007/s40262-015-0360-5. Clin Pharmacokinet. 2016. PMID: 26715213 Free PMC article. Clinical Trial.

8

Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy.

Mwasakifwa GE, Moore C, Carey D, Amin J, Penteado P, Losso M, Lim PL, Mohapi L, Molina JM, Gazzard B, Cooper DA, Boyd M; SECOND-LINE Study Group. Mwasakifwa GE, et al. AIDS. 2018 Jan 28;32(3):357-361. doi: 10.1097/QAD.0000000000001688. AIDS. 2018. PMID: 29309346 Clinical Trial.

9

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, Cooper DA; Rosey investigators. Carr A, et al. Lancet. 2004 Feb 7;363(9407):429-38. doi: 10.1016/S0140-6736(04)15489-5. Lancet. 2004. PMID: 14962523 Clinical Trial.

10

Restorative interventions for HIV facial lipoatrophy.

Carey D, Liew S, Emery S. Carey D, et al. AIDS Rev. 2008 Apr-Jun;10(2):116-24. AIDS Rev. 2008. PMID: 18615122 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

63 results

Search Page